Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News19 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General18 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News18 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland